45 results about "Plaque rupture" patented technology

A computer system and method are disclosed for automatically generating a vascular model of a blood vessel to support, for example, identification of mechanical factors corresponding to the blood vessel. The method includes interpolating data points corresponding to a contour of the blood vessel; generating a structural model representing three-dimensional structural characteristics of the blood vessel based on interpolated contours; generating a fluid model representing three-dimensional characteristics of fluid flow within the vessel; and generating a vascular model based on the structural model and the fluid model. The method may also include performing a mechanical analysis of the vascular model to identify a mechanical factor associated with the vessel, for example, a factor associated with a potential plaque rupture within the vessel. Embodiments of the invention are applicable to the diagnosis, assessment, or treatment of cardiovascular diseases.

The invention relates to predicting which individuals are at risk of developing atherosclerotic vascular disease, and once having disease, which individuals are at risk of experiencing plaque rupture which, depending on the site of the plaque, could produce myocardial infarction, stroke, critical limb ischemia, or other vascular event. The invention further relates to methods of diagnosing and aiding in the diagnosis of vascular conditions such as atherosclerosis, premature coronary artery disease and coronary artery disease, by detecting a resistin gene product in an individual. The invention further relates to methods of predicting, and aiding in predicting, the likelihood that an individual will experience a vascular event, such as but not limited to, a myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack (TIA), or critical limb ischemia.

The invention relates to predicting which individuals are at risk of developing atherosclerotic vascular disease, and once having disease, which individuals are at risk of experiencing plaque rupture which, depending on the site of the plaque, could produce myocardial infarction, stroke, critical limb ischemia, or other vascular event. The invention further relates to methods of diagnosing and aiding in the diagnosis of vascular conditions such as atherosclerosis, premature coronary artery disease and coronary artery disease, by detecting a resistin gene product in an individual. The invention further relates to methods of predicting, and aiding in predicting, the likelihood that an individual will experience a vascular event, such as but not limited to, a myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack (TIA), or critical limb ischemia.

Matrix metalloprotease inhibiting compounds, pharmaceutical compositions thereof and a method of disease treatment using such compounds are presented. The compounds of the invention have the generalized formulas: wherein r is 0-2, T is selected from and R40 is a mono- or bi-heterocyclic structure.These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, corneal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibular joint disease, demyelating diseases of the nervous system, tumor metastasis or degenerative cartilage loss following traumatic joint injury, and coronary thrombosis from athrosclerotic plaque rupture. The present invention also provides pharmaceutical compositions and methods for treating such conditions.

Atherosclerosis can be viewed as a response to injury and it is not atherosclerosis per se that is serious but instead factors leading to rupture of atherosclerotic plaques. In the present invention we have identified such factors. A decreased binding of Annexing V to the endothelium was seen in patients with a history of atherothrombosis. The use of native Annexin V or an N-terminal fragment as an active component or a subfraction of immunoglobulins to manufacture a pharmaceutical composition is proposed to improve said binding. The use of Annexin V, N-terminal fragments or immunoglobulins to increase the Annexin V-binding to carotid plaque represents novel mechanism for preventing atherothrombosis.

A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. The pharmaceutically acceptable carrier may be a hydrophilic polymer.

The invention provides a multi-dimensional plaque rupture risk early-warning system, wherein an acquired CCTA easy-damage plaque automatic identification method is combined with CT real-time blood flow dynamics analysis technology based on deep learning, thereby creating a noninvasive plaque rupture risk early-warning model with higher efficiency, higher sensitivity and higher accuracy, and supplying a comprehensive and reliable basis and a key technical means for intelligent noninvasive accurate detection and early warning of coronary artery plaque rupture.

The invention discloses a method for cultivating an edible fungus of xiuzhen genus, relating to edible fungi. Cultivate the parent species of edible fungus PDA with PDA slant medium. The original species uses wheat grains as the substrate. After the wheat grains are soaked in water, calcium carbonate is added for inoculation and cultivation; Inoculate when the temperature in the cultivation bag drops to 23-26°C, and then place the cultivation bag in the cultivation room for cultivation. When the strain germinates and the mycelium grows to half the height of the cultivation bag, the buckle of the bag is loosened; when the temperature is lower than 20°C, add Temperature to 23-26°C, after 30-40 days of cultivation, after the mycelia are covered with the cultivation bag, it enters the physiological maturity stage, that is, the bag is opened, and then sprayed with water after covering the soil; after 7-10 days after covering the soil, the white mycelia crawls On the soil surface, after the soil surface is covered with thick white hyphae, stop spraying water, control the relative humidity of the air at 85% to 95%, and control the cultivation temperature at 20 to 30°C. Harvesting is suitable when the fungus film has not yet ruptured and opened the umbrella.

The invention discloses a simplified calculation method based on coronary artery multimode image crack formation and expansion and a plaque fracture risk quantification evaluation system, and the method comprises the steps: obtaining multimode images, such as coronary artery angiography images and intracavity images (such as optical coherence tomography), through an image input module; respectively segmenting and registering interested blood vessels or plaques on different images by adopting an image processing technology, and quantitatively obtaining anatomical indexes of lesion coronary plaques; and further calculating the distribution of the dynamic indexes of the superficial wall based on time sequence coronary angiography and determining a relatively high-risk position along the longitudinal direction of the blood vessel so as to obtain a fatigue risk coefficient formed by the local crack of the superficial wall. According to the method, the anatomical indexes of the coronary artery multi-modal image are combined, and the quantitative assessment of the crack formation based on the superficial surface of the coronary artery and the plaque crack propagation risk based on the cross section image are further added, so that the plaque fracture process is assessed more completely and comprehensively.

The invention provides a method and a system for obtaining a four-dimensional blood vessel deformation behavior and in-vivo stress of a blood vessel wall. The method combines a three-dimensional image reconstruction technology and a discrete approximation theory to realize the big deformation behavior and the in-vivo stress of the blood vessel wall. The innovations of the invention are that the change of an anatomic form of healthy or pathological vessels in a cardiac cycle along with the time can be intuitively researched for a stent to intervene pre-operation evaluation and selection of a treatment strategy; a change condition of the in-vivo stress distribution of the blood vessel wall can be also provided for plaque rupture prediction and diagnosis, so that a new method is provided for quantitative description of kinematics characteristics of the blood vessel wall and the in-vivo stress of the blood vessel wall.

The invention provides application of a reagent in the preparation of a kit; the kit is used for diagnosing acute coronary syndrome; the reagent is used for detecting at least one of miR-155-5p, miR-483-5p, and miR-451a. The inventor discovers through experiments that miR-155-5p, miR-483-5p or miR-451a has significant expression differences before and after plaque rapture, and has good diagnostic value in the early diagnosis for the rapture of coronary plaque; the kit prepared with the reagent for detecting at least one of miR-155-5p, miR-483-5p, and miR-451a is effectively applicable to the early diagnosis of the rupture of coronary plaque, and has the advantages of high sensitivity and high specificity.

A multi-dimensional plaque rupture risk early warning system provided by the present invention integrates the obtained CCTA vulnerable plaque automatic identification method with deep learning-based CT real-time hemodynamic analysis technology to create a more efficient, sensitive and accurate The non-invasive plaque rupture risk early warning model provides a comprehensive and reliable basis and key technical means for the intelligent non-invasive accurate detection and early warning of coronary plaque rupture.

The invention discloses a simplified calculation method based on the formation and expansion of coronary multi-mode image cracks and an evaluation system for quantifying the risk of plaque rupture, which acquires coronary angiography images and intracavity images (such as optical coherence tomography) through an image input module Using image processing technology to segment and register interested blood vessels or plaques on different images, and quantitatively obtain the anatomical indexes of diseased coronary plaques, and further calculate superficial plaques based on time-series coronary angiography The distribution of wall dynamics indices and the determination of relatively high-risk locations along the longitudinal direction of the vessel to obtain the fatigue risk factor for localized crack formation in the superficial wall. The present invention combines the anatomical indicators of coronary multimodal images, and further increases the quantitative assessment of the risk of plaque crack expansion based on superficial coronary crack formation and cross-sectional images, so as to evaluate plaque more completely and comprehensively. rupture process.

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, advanced atherosclerosis / plaque rupture, ischemia / reperfusion, hypertension, restenosis, cardiac calcification, allo / xenograft valvular calcifications, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and / or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. Moreover, the present invention is further based in part on the generation and phenotypic characterization of transgenic knockout homozygous rchd534 mutant mice which display characteristic cardiovascular disease symptoms. Such transgenic knockout homozygous rchd534 mutant mice are useful models for the analysis and characterization of rchd534 protein involvement in development and homeostasis of the cardiovascular system and tissue-specific regulation of the TGF-beta signaling pathways.

The present invention provides methods and compositions for treating arteriosclerotic vascular diseases by cyclohexenone compounds. In some embodiments, the compound in the methods inhibits PDGF-stimulated smooth muscle cell proliferation or migration. In some embodiments, the atherosclerosis is associated with coronary artery disease, aneurysm, arteriosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plaque rupture, Kawasaki disease, calcification or inflammation. In some embodiments, the compound lowers low-density lipoprotein (LDL) cholesterol in the subject. In some embodiments, the compound maintains a normal low-density lipoprotein (LDL) cholesterol level in the subject.